Y
Yanling Ren
Researcher at Zhejiang University
Publications - 36
Citations - 304
Yanling Ren is an academic researcher from Zhejiang University. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 8, co-authored 27 publications receiving 218 citations.
Papers
More filters
Journal ArticleDOI
Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome : Comparison of T-cell lymphoma with and without hemophagocytic syndrome
Hongyan Tong,Yanling Ren,Hui Liu,Feng Xiao,Wenyuan Mai,Haitao Meng,Wenbin Qian,Jian Huang,Lingping Mao,Ying Tong,Lei Wang,Jiejing Qian,Jie Jin +12 more
TL;DR: It is suggested that in patients presenting with fever, hepatosplenomegaly, cytopenia, and constantly increasing levels of serum LDH, CA125, ferritin, transglutaminase, and β2-microglobulin, T-LAHS should be taken into account.
Journal ArticleDOI
Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
Lingxu Jiang,Yingwan Luo,Shuanghong Zhu,Lu Wang,Liya Ma,Hua Zhang,Chuying Shen,Wenli Yang,Yanling Ren,Xinping Zhou,Chen Mei,Li Ye,Weilai Xu,Haiyang Yang,Chenxi Lu,Jie Jin,Hongyan Tong +16 more
TL;DR: Integration of the IPSS with mutation status/burden of certain MDS‐relevant genes may improve the prognostication of patients with LR‐MDS and could help identify those with worse‐than‐expected prognosis for more aggressive treatment.
Journal ArticleDOI
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms
Xingnong Ye,Xinping Zhou,Juying Wei,Gaixiang Xu,Ying Li,Liping Mao,Jian Huang,Yanling Ren,Chen Mei,Jinghan Wang,Yinjun Lou,Liya Ma,Wenjuan Yu,Li Ye,Lili Xie,Yin-Wan Luo,Chao Hu,Lin-Mei Niu,Min-Hua Dou,Jie Jin,Hongyan Tong +20 more
TL;DR: It is demonstrated that epigenetic priming with decitabine followed by low-dose idarubicin/ytarabine has an increased anti-leukemia effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Journal ArticleDOI
Homoharringtonine affects the JAK2‐STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells
TL;DR: This work tries to explore the effect of HHT on JAK2‐STAT pathway in AML cells, thus supplying theoretical basis for wider use of H HT.
Journal ArticleDOI
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes
Peipei Lin,Yanling Ren,Xiaomei Yan,Yingwan Luo,Hua Zhang,Meenu Kesarwani,Jiachen Bu,Di Zhan,Yile Zhou,Yile Zhou,Yuting Tang,Shuanghong Zhu,Weilai Xu,Xinping Zhou,Chen Mei,Liya Ma,Li Ye,Chao Hu,Mohammad Azam,Wei Ding,Jie Jin,Gang Huang,Hongyan Tong +22 more
TL;DR: This study found that NRF2 expression levels in bone marrow from high-risk patients exceeded that of low-risk MDS patients, and suggested that targetingNRF2 in combination with conventional chemotherapy could pave the way for future therapy for high- risk MDS.